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To Editor, Journal of Nephrology
Dear Editor,
herewith you find the manuscript Osteocalcin (bone GLA protein) levels, vascular
calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes
mellitus, which I submit for publication as an original article in the Journal of
Nephrology.
Diabetes Mellitus (DM) is one of the major causes of end stage kidney disease.
Patients with DM and Chronic kidney disease (CKD) have greater severity of CKD
associated complications, in particular, they are inclined to micro and macro-vascular
complications, and earlier and progressive bone disorders, such as osteoporosis,
adynamic bone disease and fractures.
Bone Gla Protein (BGP or osteocalcin, OC) is a vitamin K-dependent protein, secreted
by osteoblasts and involved in the regulation of bone matrix mineralization. Levels of
BGP in DM patients on hemodialysis (HD) have been poorly described. Our goal was
to characterize BGP and ucBGP in DM patients on HD, compared to HD patients
without DM, and their association with vascular and bone disease.  To our knowledge,
this is the first study in hemodialysis patients suggesting a potential protective role of
BGP in the context of bone, endocrine and vascular pathway.
The general message  is the need to pay attention to vitamin K levels to prevent bone
and vascular damage both in general population and in CKD patients, especially in DM
CKD patients.  Indeed we hope that our findings will raise awareness and inspire other
physicians to carry out research  about the importance of vitamin K and its Vitamin K
Dependet Proteins in the development of vascular calcification and bone fractures,
both  risk factors for the main cause of morbidity and mortality.
The paper is original and is not under consideration by any other journal.
Thanking you for your attention.
Yours sincerely
Maria Fusaro, MD, PhD
Suggested Reviewers:
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Padua, 14 October 2018 
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Dear Editor, 
herewith you find the manuscript Osteocalcin (bone GLA protein) levels, vascular calcifications, 
vertebral fractures and mortality in hemodialysis patients with diabetes mellitus, which I 
submit for publication as an original article in the Journal of Nephrology. 
Diabetes Mellitus (DM) is one of the major causes of end stage kidney disease. Patients with DM 
and Chronic kidney disease (CKD) have greater severity of CKD associated complications, in 
particular, they are inclined to micro and macro-vascular complications, and earlier and progressive 
bone disorders, such as osteoporosis, adynamic bone disease and fractures.  
Bone Gla Protein (BGP or osteocalcin, OC) is a vitamin K-dependent protein, secreted by 
osteoblasts and involved in the regulation of bone matrix mineralization. Levels of  BGP in DM 
patients on hemodialysis (HD) have been poorly described. Our goal was to characterize BGP and 
ucBGP in DM patients on HD, compared to HD patients without DM, and their association with 
vascular and bone disease.  To our knowledge, this is the first study in hemodialysis patients 
suggesting a potential protective role of BGP in the context of bone, endocrine and vascular 
pathway. 
The general message  is the need to pay attention to vitamin K levels to prevent bone and vascular 
damage both in general population and in CKD patients, especially in DM CKD patients.  Indeed 
we hope that our findings will raise awareness and inspire other physicians to carry out research  
about the importance of vitamin K and its Vitamin K Dependet Proteins in the development of 
vascular calcification and bone fractures, both  risk factors for the main cause of morbidity and 
mortality. 
 
The paper is original and is not under consideration by any other journal.  
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Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and 1 
mortality in hemodialysis patients with diabetes mellitus.  2 
ABSTRACT 3 
BACKGROUND & AIMS: Diabetes Mellitus is recognized as one of the major causes of end stage 4 
kidney disease. Bone Gla protein (BGP) is a vitamin K-dependent protein involved in bone 5 
mineralization and vascular calcifications (VC). Our goal was to characterize BGP and 6 
undercarboxylated BGP (ucBGP) in DM patients on HD, compared to HD patients without DM, and 7 
their association with vascular and bone disease.   8 
METHODS: 387 HD patients from 18 dialysis centers in Italy. Associations of DM, levels of BGP,  9 
vitamin D and VC were evaluated. Time-to-event analysis for all-cause mortality was performed by 10 
the Kaplan-Meier. 11 
RESULTS: Patients with DM had lower levels of total BGP (139.00 vs. 202.50 mcg/L, p<0.001), 12 
25(OH)D (23.4 vs. 30.2 ng/ml, p<0.001), and ucBGP (9.24 vs. 11.32 mcg/L, p=0.022). In regression 13 
models, the geometric means of total BGP and ucBGP were 19% (p=0.009) and 26% (p=0.034) lower 14 
in diabetic patients. In univariate Cox regression analysis, DM patients had a higher risk of all-cause 15 
mortality (HR:1.83, 95% CI:1.13-2.96, p=0.014). Adjustment for confounders  confirmed the 16 
significant DM-mortality link. We included VC and warfarin into the Cox model, the DM-mortality 17 
link was no longer significant, suggesting a role of these risk factors as causal mediators leading to 18 
increased mortality in dialysis patients. 19 
CONCLUSIONS: HD patients have an increased mortality risk associated with DM. Furthermore, 20 
we found an association between DM and decreased BGP levels. To our knowledge this is the first 21 
study in HD patients suggesting a potential protective role of BGP in the bone, endocrine and vascular 22 
pathway.  23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
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 32 
Introduction 33 
Diabetes Mellitus (DM) is one of the major causes of end stage kidney disease. Patients with DM and 34 
Chronic kidney disease (CKD) have greater severity of CKD associated complications compared to 35 
CKD patients with other etiologies of kidney disease. In particular, DM patients are inclined to micro 36 
and macro-vascular complications, and earlier and progressive bone disorders, such as osteoporosis, 37 
adynamic bone disease and fractures (1).  38 
Bone Gla Protein (BGP or osteocalcin, OC) is a vitamin K-dependent protein, secreted by osteoblasts 39 
and involved in the regulation of bone matrix mineralization. Carboxylated osteocalcin (Gla-40 
containing cBGP) is involved in bone crystal nucleation by its specific affinity to bind hydroxyapatite 41 
molecules. In contrast, ucBGP (ucBGP or ucOC) has less than 3 carboxylated residues and a lower 42 
affinity for bone tissue. An endocrine role of ucOC has been recently identified (2, 3). It seems to be 43 
able to increase insulin secretion directly by stimulating pancreatic β cells, or indirectly by promoting 44 
the release of adiponectin (4).  45 
BGP also has a protective role in vascular calcifications in humans (5), acting under the genetic 46 
control of vitamin D. Vitamin D deficiency is highly prevalent in CKD patients, suggesting that the 47 
protective role of vitamin D on vascular calcification (6) may be mediated by a reduced expression 48 
of BGP and other vitamin K dependent proteins involved in calcification pathways, such as Matrix 49 
Gla Protein, a potent inhibitor of vascular calcifications (7).  50 
Levels of  BGP in DM patients on hemodialysis (HD) have been poorly described. Therefore, our 51 
goal was to characterize BGP and ucBGP in DM patients on HD, compared to HD patients without 52 
DM, and their association with vascular and bone disease.   53 
 54 
Methods  55 
We performed a secondary analysis of the VIKI (VItamin K Italian) study (8), involving 387 56 
hemodialysis patients from 18 dialysis centers in Italy. Local ethics committees approved the study. 57 
Inclusion criteria were both genders, on hemodialysis for >1 year, and their written informed consent; 58 
exclusion criteria were patients with life expectancy < 6 months, diagnosis of cancer (with the 59 
exception of basal cell carcinoma), coagulation disorders, or conditions potentially interfering with 60 
study outcomes. 61 
Data on DM were collected in 85 patients. We reported general features, type of dialysis, 62 
comorbidities and biochemical profiles.  63 
 64 
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 65 
Laboratory tests 66 
Parathyroid Hormone (PTH)  67 
Serum PTH was measured by automated LIAISON® N-Tact® PTH Assay 310910 (DiaSorin Inc., 68 
Stillwater MN, USA), a direct, 2-site, sandwich-type chemiluminescence immunoassay (CLIA) 69 
carried out on the LIAISON® (DiaSorin Inc., Stillwater MN, USA) instrument. The analytical 70 
sensitivity is 1 pg/mL and the intra-assay and inter-assay CVs were 3.7-6.3 and 3.5-5.3%, 71 
respectively.  72 
25-OH Vitamin D  73 
For quantitative determination of total 25-OH vitamin D (both D2 and D3 form) in serum, we used 74 
the automated LIAISON® 25 OH Vitamin D TOTAL Assay 310600, a direct competitive CLIA 75 
executed on the LIAISON (DiaSorin Inc., Stillwater MN, USA) instrument. The analytical sensitivity 76 
is <10 nmol/L, and the intra-assay coefficients of variation (CV) were between 2.9 and 5.5%, while 77 
the inter-assay CV is 6.3-12.9%.  78 
Total BGP  79 
The method for the quantitative determination of total BGP in serum was the automated LIAISON® 80 
Osteocalcin Assay 310950 (DiaSorin Inc., Stillwater MN, USA), a direct, 2-site, sandwich-type CLIA 81 
executed on the LIAISON® (DiaSorin Inc., Stillwater MN, USA) instrument. The analytical 82 
sensitivity is <0.3 ng/mL and the intra-assay CV is 3-8%, while the inter-assay CV is 4-9%.  83 
Undercarboxylated BGP (ucBGP)  84 
For quantitative determination of ucBGP, we used the Glu-osteocalcin Enzyme Immunoassay (EIA) 85 
Kit MK118 (Takara Bio Inc., Otsu, Shiga, Japan), a manual solid-phase EIA based on a sandwich 86 
method that utilizes 2 mouse monoclonal anti-ucBGP antibodies to detect ucBGP by a 2-step 87 
procedure. One of the mouse monoclonal anti-undercarboxylated BGPs is immobilized onto the 88 
micro-titre plate and blocked against non-specific binding. Samples are added to each well and 89 
incubated. The second step is to wash the plate and to add the second anti-BGP labelled with 90 
peroxidase (POD). The reaction between POD and substrate (H2O2 and 3,3’, 5,5’ tetramethyl-91 
benzidine) results in color development with intensities proportional to the amount of ucBGP present. 92 
The analytical sensitivity is 0.25 ng/mL and the intra-assay and inter-assay CVs are 4.4-6.7 and 5.7-93 
9.9%, respectively.  94 
 95 
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 96 
Total matrix GLA protein (MGP) 97 
The quantitative determination of MGP was performed using the Human MGP—Matrix Gla Protein 98 
Kit (Biomedica Medizinprodukte GmbH & Co KG, Wien, A). It is a manual competitive ELISA 99 
method designed to detect MGP in serum. The analytical sensitivity is 0.3 nmol/L, and the intra-assay 100 
and inter-assay coefficients of variation (CVs) are 5–6 and 7–9 %, respectively.  101 
Undercarboxylated MGP (ucMGP) 102 
The measurement of the total undercarboxylated Matrix GLA Protein was performed by VitaK using 103 
a competitive ELISA, as described previously (9). The analytical sensitivity is 21 nmol/L, and the 104 
intra-assay and inter-assay CVs have been found to be 8.9 and 11.4 %, respectively. 105 
Statistical analysis 106 
Normally distributed data were summarized as mean ± standard deviation (SD), non-normally 107 
distributed data as median and interquartile range (IQR), and binary/categorical data as percentages, 108 
as appropriate. Categorical variables between two groups were compared by 2 test or Fisher’s exact 109 
method. The comparison between medians was performed by the Mann-Whitney rank test whereas 110 
means were compared by unpaired T-Test.   111 
To assess associations between log transformed values of total and ucBGP (outcome 112 
variables) and diabetes mellitus two multiple linear regression models were built. Variables available 113 
for the analysis were: gender, age, renal failure history, alcohol consumption, medical history (cardio 114 
and cerebrovascular disease, diabetes mellitus, malabsorption syndrome and liver disease), BMI, 115 
routine biochemical examinations, and mineral and bone disorders treatment (oral calcitriol, vitamin 116 
D analogues, calcimimetics, and phosphate-binding drugs) (table 1 supplementary). In multiple 117 
regression models we included all factors that were associated with the outcome in univariate 118 
analyses.  119 
Time-to-event analysis for all-cause mortality related to DM was performed by the Kaplan-120 
Meier method. To infer the involvement of DM in the pathophysiological pathway leading to death 121 
we applied an analytical approach (10): We estimated the independent relationship between DM and 122 
mortality by multiple Cox proportional-hazard models of increasing complexity. In the unadjusted 123 
analysis (Model 1) we included DM alone. In Model 2 we introduced DM patients plus potential 124 
confounders hypertension, angina, myocardial infarction, age, BMI, dialysis vintage. Finally, to 125 
unravel the potential pathogenic pathway by which diabetes mellitus could increase the mortality risk 126 
in dialysis patients we added into the multivariate Cox regression analysis two potential mediators 127 
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(that is, variables potentially involved in the pathogenesis pathway between the exposure and the 128 
outcome) of such an effect. Such mediators were peripheral vascular disease (Model 3) and warfarin 129 
(Model 4). The proportionality assumption was assessed by visual inspection and no violation was 130 
found. Hazard ratio (HR) and 95% confidence intervals (CIs) were calculated.  131 
All statistical analyses were performed using SAS statistical package (version 9.3, SAS, Cary, 132 
NC). 133 
 134 
Results 135 
Main demographic and clinical characteristics of the study population are summarized in table 136 
1. Patients with DM (85, 22%; 31 males, 54 females) had higher BMI than patients without DM 137 
(27.62 vs 23.94, p < 0.001). No significant differences between the two groups were observed as for 138 
age and smoking. Patients with DM had a shorter history of dialysis (37.0 vs 54.5 months; p<0.001), 139 
and a higher prevalence of hypertension (90.6% vs 75.2%; p=0.002), myocardial infarction (27.1% 140 
vs 16.6%; p=0.029), and aortic and peripheral vascular disease (table 2). In DM patients, mild to 141 
severe aortic calcifications were more frequently observed than in patients without DM (90.6% vs 142 
77.8%, p=0.008) and this was also true for iliac calcifications. In particular, severe iliac calcifications 143 
were significantly worse in DM (9.4% vs 2.7%, P=0.006). 144 
 145 
Diabetes Mellitus, total BGP and ucBGP 146 
Patients with compared to without DM had significant lower levels of total BGP (139.00 vs. 147 
202.50 mcg/L, p<0.001), ucBGP (9.24 vs. 11.32 mcg/L, p=0.022), and 25(OH) vitamin D (23.4 vs. 148 
30.2 ng/ml, p<0.001) (table 1, fig 1). 149 
Lower total BGP levels were associated with aortic calcification (p<0.001), iliac calcification 150 
(p=0.01) and vertebral fractures (p<0.01). In DM patients in treatment with warfarin (n=16, 8.8%), 151 
total BGP and ucMGP were significantly lower (56.2 vs. 152 mcg/L, p<0.001 and 336 vs. 616 152 
nmol/L, p=0.038), respectively (supplementary table 2).  153 
The regression model showed that DM patients had a statistically significant reduction of 19% of 154 
geometric mean both of total BGP (parameter estimate=-0.21092; p=0.009; R2=0.53) and of 25.6% 155 
of geometric mean of ucBGP (parameter estimate=-0.29634; p=0.034; R2=0.17), (table 3, table 4). 156 
 157 
Survival Analysis 158 
A total of 77 patients died during the follow-up (average time of observation: 2.7±0.5 years). Most 159 
patients died of cardiovascular events (n=49); other causes were infections (n=11), cancer (n=5) and 160 
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miscellaneous (n=12). Kaplan-Meier survival analysis showed that patients with DM had a lower 161 
probability of survival when compared to those with no DM (Fig. 2) and the difference was of high 162 
statistical significance (Log Rank Test, p=0.0013). Accordingly, on univariate Cox regression 163 
analysis, DM patients had a higher risk of all-cause mortality (HR: 1.83, 95% CI: 1.13-2.96, p=0.014) 164 
(fig 2). Data adjustment for confounders (hypertension, angina, myocardial infarction, age, BMI, 165 
dialysis vintage) confirmed the link between DM and mortality (HR=1.73 95% CI 1.03-2.90 p=0.038) 166 
(table 5, model 2). In models including peripheral vascular disease alone (table 5, model 3; HR=1.43 167 
95% CI 0.82-2.48 p=0.206) or in combination with warfarin (table 5, model 4; HR=1.31 95% CI 168 
0.75-2.28 p=0.342), the DM-mortality link was not significant. Of note,  forcing total BGP or ucBGP 169 
into the model 4 in table 5, did not affect the DM-mortality link which remained not significant 170 
(P>0.28). In these models, neither total BGP (HR: 1.00, 95% CI: 0.99-1.01, P=0.36) nor ucBGP (HR: 171 
0.99, 95% CI: 0.98-1.01, P=0.33) significantly predicted the study outcome. 172 
 173 
Discussion 174 
Our study shows a significant reduction of total and ucBGP levels in patients affected by DM and 175 
CKD, in contrast to other patients affected by different nephropathies, confirmed in the regression 176 
model.   177 
We know that BGP is not only involved in bone matrix mineralization, but it is also a mediator 178 
in endocrine pathway.  The endocrine role of BGP seems to be related to its undercarboxylated form, 179 
while the process of carboxylation is necessary for the protein activation in bone tissue (11). 180 
Endocrine functions are strictly connected with glucose metabolism, thus preponderant for bone 181 
metabolism in DM patients. The endocrine role consists in regulating glucose homeostasis by 182 
promoting the secretion of insulin from pancreatic beta-cells and by increasing adiponectine 183 
expression, an anti-inflammatory protein secreted by adipocytes. These actions finally result into a 184 
greater insulin sensitivity. In fact, in mice, administration of ucOC was able to increase the insulin 185 
and adiponectin secretion and stimulated glucose and lipid catabolism (12). BGP requires vitamin K 186 
for its activity. Clinical trials have reported contrasting results about the effects of vitamin K on 187 
insulin sensitivity. A recent meta-analysis including eight trials involving 1,077 participants 188 
suggested no effect of vitamin K supplementation on insulin sensitivity (13).  In contrast, other 189 
authors reported that Vitamin K2 administration could improve glycemic status in DM rats by 190 
induction of BGP gene expression (14). Moreover, Choi et al. found a positive effect of vitamin K2 191 
supplementation in increasing insulin sensitivity in healthy young men via BGP metabolism (15). 192 
According to the literature, in our DM population aortic and iliac calcifications were significantly 193 
more prevalent than in patients without DM. Vascular calcifications are considered strong predictors 194 
of cardiovascular disease, closely connected with morbidity and mortality (8). Evidence indicates that 195 
7 
 
vascular calcification is a process of active bone formation regulated by stimulators and inhibitors of 196 
calcification. BGP is known to be involved in preventing vascular aortic calcifications, through direct 197 
and indirect mechanisms. Indirect mechanisms are mediated by its action on insulin, in particular in 198 
the context of metabolic acidosis associated to bone reabsorption, very common in the CKD 199 
population, or by the release of adiponectin. Adiponectin may prevent the trans-differentiation of 200 
vascular smooth muscle cells into osteoblast-like cells in arterial vessels (16). Data are available not 201 
only in rats with CKD, but also in humans. In fact, higher total BGP levels were found associated 202 
with lower abdominal aortic calcification progression rate and lower mortality in a 10 year-long 203 
prospective study in elderly Caucasian subjects, showing total BGP as an independent factor of 204 
cardiovascular risk and mortality (17). Moreover, in the hemodialysis population we showed that low 205 
levels of total-BGP are associated with vertebral fractures, aortic and iliac calcifications (5). Finally, 206 
a recent review reported low BGP levels as a biomarker of abdominal aortic calcification in patients 207 
with diabetes (18).  208 
In the univariate Cox regression analysis, DM patients were found to have a higher risk of all-cause 209 
mortality (p=0.014). Although we did not find that BGP levels predict mortality, we cannot exclude 210 
that their lower levels may lead to a reduced protection of bone and vascular health, increasing 211 
cardiovascular mortality. Regarding crude and adjusted HR for all-cause mortality in relation to DM 212 
(table 5), data adjustment for possible confounders (hypertension, angina, myocardial infarction, age, 213 
BMI, dialysis vintage) did not affect the significant link between DM and mortality, indicating that 214 
this association cannot be explained by confounding factors themselves. Thus, we would like to 215 
underline that when we forced into the model two other factors - vascular calcifications and warfarin 216 
- the association between DM and mortality became not significant, suggesting that vascular 217 
calcifications and warfarin use may be mediators but not confounders in the potential pathogenic 218 
pathways underlying the relationship between DM and mortality.  219 
Finally, in the sub-analysis regarding warfarin treated DM patients, we observed reduced 220 
levels of BGP and ucMGP. The association of lower serum ucMGP, rather than total MGP, with 221 
atherosclerosis and vascular calcification has been previously reported in the CKD population (9). In 222 
a study conducted in patients affected with cardiovascular disease, Parker et al. reported that  reduced 223 
kidney function was associated with lower serum ucMGP levels, suggesting MGP as a potential 224 
marker of vascular calcification and cardiovascular disease in the CKD population (19). Warfarin, 225 
acting as a vitamin K antagonist, may inhibit vitamin-K dependent proteins that are involved in bone 226 
mineralization and the prevention of vascular calcification, including BGP and MGP.  We already 227 
reported that in hemodialysis patients warfarin use was associated with an increase of aortic and iliac 228 
calcifications, with significantly lower BGP levels, and ucMGP levels (20). 229 
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DM and CKD patients have a high prevalence of low vitamin D levels and our study also 230 
shows a significant reduction of vitamin D levels in DM patients. Recent evidence suggested the 231 
important role of vitamin D in the pathogenesis of DM and CKD, reporting that low vitamin D levels 232 
are associated with poor outcomes, in particular with progression of DM and cardiovascular disease 233 
(21). Moreover, in hemodialysis patients, we found a significant and independent association between 234 
low 25(OH) vitamin D levels and severe vascular calcifications, assuming a possible protective role 235 
of vitamin D on vascular calcifications by its action on vitamin K dependent proteins, such as BGP 236 
and MGP (6). In our previous study we showed that vitamin D analogues can improve vitamin K 237 
dependent protein levels.  In particular, administration of vitamin D was associated with increased 238 
BGP levels in hemodialysis patients (22). These data support the potential role of vitamin D 239 
supplementation as a preventative and therapeutic agent for bone and vascular health in DM and CKD 240 
patients.  241 
Finally, we underscore the interesting associations of total BGP with PTH and ALP, which 242 
could be explained by two factors: Vitamin D control on BGP (low vitamin D levels in DM patients 243 
could damage this function) and a higher bone turnover, resulting in higher BGP and ucBGP. All of 244 
this reveals a remarkable role of BGP as bone biomarker in the scenery of CKD-MBD. 245 
In conclusions, in hemodialysis patients we confirmed an increased mortality associated to DM and 246 
we found an association between diabetic status and decreased BGP levels. To our knowledge, this 247 
is the first study in hemodialysis patients suggesting a potential protective role of BGP in the context 248 
of bone, endocrine and vascular pathway. Further investigations are needed to assess the clinical 249 
implications of low BGP levels in hemodialysis patients affected by DM. 250 
 251 
 252 
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 262 
 263 
Table 1. Patients characteristics. 264 
 
Patients 
With DM 
(n=85, 22%) 
Patients  
Without DM 
(n=302, 78%) p-value 
Gender, female, n (%) 31 (36.5 %) 114 (37.7 %) 0.830 
Age, years, median 68 (63, 73.50) 67 (52, 74) 0.132 
Weight, kg, median 76.50 (67.75, 87.75) 67 (58.5, 75.63) < 0.001 
Height, m, median 1.65 (1.60, 1.75) 1.68 (1.60, 1.73) 0.491 
BMI, kg/cm2, median 27.62 (24.42, 30.89) 23.94 (21.29, 26.72) < 0.001 
Smokers, n (%) (n=370) 
        Yes 
        No 
        Ex 
 
47 (57.3%) 
25 (30.5%) 
10 (12.2%) 
 
187 (64.9%) 
60 (20.8%) 
41 (14.3%) 
0.186 
Current or former alcohol drinkers, n (%) (n=361) 62 (21.8%) 20 (26%) 0.442 
Medical history    
Dialysis vintage, months, median 37 (26, 58) 54.5 (29.75, 113.25) < 0.001 
Type of dialysis, n (%) 
Bicarbonate dialysis 
Hemofiltration (HF) 
Hemodiafiltration (HDF) 
Acetate free biofiltration (AFB) 
Other types of dialysis 
 
34 (40.0%) 
11 (12.9%) 
21 (24.7%) 
16 (18.8%) 
3 (3.6%) 
 
155 (51.3%) 
21 (7%) 
81 (26.8%) 
38 (12.6%) 
7 (2.3%) 
0.138 
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Patients 
With DM 
(n=85, 22%) 
Patients  
Without DM 
(n=302, 78%) p-value 
Previous kidney transplant, n (%) 2 (2.4%) 52 (17.2%) < 0.001 
Hypertension, n (%)  77 (90.6%) 227 (75.2%) 0.002 
Angina, n (%) 19 (22.4%) 45 (14.9%) 0.102  
Myocardial infarction, n (%) 23 (27.1%) 50 (16.6%) 0.029 
Atrial fibrillation, n (%) 14 (16.5%) 37 (12.3%) 0.310 
Heart failure, n (%) 10 (11.8%) 29 (9.6%) 0.559 
Peripheral vascular disease, n (%) 
No 
Asymptomatic 
Intermittent claudication 
Amputation  
 
33 (38.8%) 
32 (37.6%) 
12 (14.1%) 
8 (9.5%) 
 
220 (72.8%) 
66 (21.9%) 
16 (5.3%) 
0 (0%) 
< 0.001 
Cerebrovascular accident, n (%) 
No 
Stroke 
Other type 
 
76 (89.4%) 
4 (4.7%) 
5 (5.9%) 
 
270 (89.4%) 
16 (5.3%) 
16 (5.3%) 
0.958 
Vertebral fractures, n (%) 44 (51.8%) 170 (56.3%) 0.458 
Vertebral fractures among men, n (%) 30 (55.6%) 115 (61.2%) 0.458 
Vertebral fractures among women, n (%) 14 (45.2%) 55 (48.2%) 0.760 
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Patients 
With DM 
(n=85, 22%) 
Patients  
Without DM 
(n=302, 78%) p-value 
Routine biochemical profile    
Ca, mg/dl, median 9.0 (8.7, 9.4) 9.1 (8.7, 9.6) 0.176 
Ca, mg/dl, mean±SD (not normally distributed) 9.08±0.59 9.18±0.70 0.225 
P, mg/dl, mean±SD (not normally distributed) 4.63±1.07 4.80±1.32 0.272 
P, mg/dl, median 4.34 (3.85, 5.35) 4.65 (3.88, 5.59) 0.338 
Alkaline phosphatase, U/L, median 87 (65, 111.5) 81 (64, 111) 0.432 
PTH, pg/ml, median 207 (135.5, 340) 244.5 (140, 401.25) 0.169 
Albumin, g/dl, median 3.9 (3.5, 4.0) 3.9 (3.5, 4.1) 0.248 
CRP, mg/L, median 2.13 (0.47, 4.1) 1.65 (0.50, 5.26) 0.802 
KT/V, mean±SD 1.26±0.25 1.25±0.27 0.633 
Aluminium, mcg/L, median 10 (7, 16) 13.8 (8, 22) 0.057 
Total cholesterol, mg/dl, median 176 (150,197.2) 165 (140, 192.3) 0.164 
Triglycerides, mg/dl, median 157 (111.5, 211) 146.5 (110, 202.3) 0.349 
HDL Cholesterol, mg/dl, median 39 (32, 49) 40 (33, 50) 0.652 
LDL Cholesterol, mg/dl, median 96 (74, 119) 89 (69, 116) 0.513 
25(OH)D, ng/mL, median 23.4 (16.5, 34.7) 30.2 (20.18, 46.78) < 0.001 
BGP total, mcg/L, median 139 (62.40, 220.5) 202.5 (109, 362) < 0.001 
ucBGP, mcg/L, median 9.24 (2.99,15.54) 11.32 (6.15, 18.15) 0.022 
12 
 
 
Patients 
With DM 
(n=85, 22%) 
Patients  
Without DM 
(n=302, 78%) p-value 
MGP total, nmol/L, median 18 (12, 31.88) 19.36 (13, 30.73) 0.582 
ucMGP, nmol/L, median 541.86 (287.40, 981.5) 572.84 (285, 930) 0.634 
Mg, mg/dL, median (n=26) 2.3 (2, 2.6) (n=113) 2.3 (2, 2.7) 0.488 
 265 
 266 
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Table 2. Presence and severity of vascular calcifications in patients with DM. 268 
 
Patients 
With DM 
(n=85, 22%) 
Patients  
No DM 
(n=302, 78%) p-value 
Aortic calcifications, n (%) 
None 
Mild + Moderate 
Severe 
 
8 (9.4%) 
47 (55.3%) 
30 (35.3%) 
 
67 (22.2%) 
149 (49.3%) 
86 (28.5%) 
0.029 
Aortic calcifications: mild, moderate or severe 
vs none, n (%) 
77 (90.6%) 235 (77.8%) 0.008 
    
    
Iliac calcifications, n (%) 
None 
Mild+ Moderate 
Severe 
 
 
31 (36.5%) 
46 (54.1%) 
8 (9.4%) 
 
139 (46%) 
155 (51.3%) 
8 (2.7%) 
0.012 
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 288 
Fig. 1. Boxplot of ucBGP, Total BGP and 25(OH)D grouped by DM. 289 
 290 
 291 
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Table 3. Regression model with outcome total BGP (log-transformed). 293 
VARIABLE 
PARAMETER ESTIMATE 
(b) 
P-VALUE 
DM -0.21 0.009 
lgPTH 0.27 < 0.0001 
lgALP 0.29 < 0.0001 
R2=0.53 294 
The stepwise analysis also identified the following variables as covariates: age, BMI, smoking status, cerebrovascular 295 
accidents, hypertension, heart failure, vascular calcification, LDL cholesterol, albumin and the following therapies: 296 
aluminium, warfarin, calcimimetics, vitamin D analogues, intravenous calcitriol and antibiotics. Other variables remained 297 
out of the model.  298 
  299 
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Table 4. Regression model with outcome ucBGP (log-transformed). 300 
VARIABLE PARAMETER ESTIMATE (b) P-VALUE 
DM -0.30  0.034 
lgPTH 0.22 0.0011 
R2=0.17 301 
 302 
The stepwise analysis also identified the following variables as covariates: phosphate, aortic calcifications, calcium-303 
phosphate, KT/V, liver disease and the following therapies: intravenous calcitriol, calcimimetics, heparin, warfarin, 304 
steroids and antiepileptics. Other variables remained out of the model.  305 
 306 
 307 
Fig. 2. Kaplan-Meier survival curves for all-cause mortality, for patients with DM (1, red line) and patients 308 
with no DM (0, blu line).  309 
 310 
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 317 
 318 
Table 5. Crude and adjusted HR for all-cause mortality in relation to DM.  319 
 Model 1 (Unadjusted)  
Model 2 
(Adjusted for 
confounders*)  
Model 3 
(Adjusted for 
confounders* 
and peripheral 
vascular 
disease)  
Model 4 (Adjusted for 
confounders*, peripheral 
vascular disease and 
warfarin)  
Patients with 
DM 
HR=1.83 95% CI 1.13-
2.96 p=0.014 
HR=1.73 95% CI 
1.03-2.90 p=0.038 
HR=1.43 95% CI 
0.82-2.48 
p=0.206 
HR=1.31 95% CI 0.75-
2.28 p=0.342 
 320 
 * Confounders: hypertension, angina, myocardial infraction, age, BMI, dialysis vintage.  321 
CI = Confidence Interval; HR = Hazard Ratio. 322 
 323 
 324 
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Table 1 supplementary. Therapy by diabetic status. 326 
 327 
Drugs prescribed to patients  
Patients 
With DM 
(n=85, 22%) 
Patients  
Without DM 
(n=302, 78%) p-value 
Warfarin (n, %) 16 (18. 8 %) 30 (9.9%) 0.025 
Steroids (n, %) 2 (2.4%)  19 (6.3%) 0.157 
Thyroid hormones (n, %) 11 (12.9%)  29 (9.6%)  0.372 
Antibiotics (n, %) 8 (9.4%) 8 (2.6%) 0.006 
Antiepileptics (n, %) 4 (4.7%) 10 (3.3%) 0.543 
Statins (n, %) 40 (47.1%) 86 (28.5%) 0.001 
Beta-Blockers (n, %) 32 (37.6%) 112 (37.1%) 0.925 
Antidiabetics (n, %) 7 (8.2%) 0 (0%) <0.001 
Insulin (n, %) 58 (68.2%) 0 (0%) <0.001 
Anti-Gastric (n, %) 64 (75.3%) 233 (77.2%) 0.720 
Aluminium (n, %) 16 (18.8%) 80 (26.5%) 0.148 
Calcium carbonate (n, %) 35 (41.2%) 97 (32.1%) 0.120 
Calcium acetate (n, %) 9 (10.6%) 12 (4.0%) 0.017 
Sevelamer (n, %) 38 (44.7%) 125 (41.4%) 0.584 
Lanthanum (n, %) 10 (11.8%) 46 (15.2%) 0.422 
Oral calcitriol (n, %) 43 (50.6%) 134 (44.4%) 0.309 
Intravenous calcitriol (n, %) 2 (2.4%) 134 (44.4%) 0.653 
19 
 
Vitamin D analogues (n, %) 12 (14.1%) 65 (21.5%) 0.131 
Calcimimetics (n, %) 11 (12.9%) 64 (21.2%) 0.089 
  328 
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Table 2 supplementary. Main characteristics of the Patients With DM and Warfarin VS Patients With DM 329 
and No Warfarin Use. 330 
 
Patients 
With DM and 
Warfarin Use 
(n=16, 18.8%) 
Patients 
With DM and No 
Warfarin Use 
 (n=69, 81.2%) p-value 
Gender, female, n (%) 8 (50 %) 23 (33.3 %) 0.212 
Age, years, median 72 (64.5, 77.50) 67 (63, 72) 0.095 
Weight, kg, median 75.25 (61.25, 81.0) 76.5 (69, 88) 0.220 
Height, m, median 1.65 (1.60, 1.78) 1.66 (1.62, 1.75) 0.596 
BMI, kg/cm2, median 26.17 (23.04, 28.05) 28.26 (24.65, 31.45) 0.144 
Smoker, n (%) (n=370) 
        Yes 
        No 
        Ex 
 
10 (62.4%) 
3 (18.8%) 
3 (18.8%) 
 
37 (56.1%) 
22 (33.3%) 
7 (10.6%) 
0.429 
Current or former alcohol drinker, n (%) (n=77) 3 (18.8%) 17 (27.9%) 0.459 
Medical history    
Dialysis vintage, months, median 42 (25, 61.5) 37 (26, 55) 0.723 
Type of dialysis, n (%) 
Bicarbonate dialysis 
Hemofiltration (HF) 
Hemodiafiltration (HDF) 
Acetate free biofiltration (AFB) 
Other types of dialysis 
 
6 (37.5%) 
2 (12.5%) 
3 (18.8%) 
5 (31.2%) 
0 (0%) 
 
28 (40.6%) 
9 (13.0%) 
18 (26.1%) 
11 (16%) 
3 (4.3%) 
0.622 
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Patients 
With DM and 
Warfarin Use 
(n=16, 18.8%) 
Patients 
With DM and No 
Warfarin Use 
 (n=69, 81.2%) p-value 
Previous kidney transplant, n (%) 1 (6.3%) 1 (1.5%) 0.254 
Hypertension, n (%) 14(87.5%) 63 (91.3%) 0.639 
Angina, n (%) 5 (31.3%) 14 (20.3%) 0.343  
Myocardial infarction, n (%) 2 (12.5%) 21 (30.4%) 0.146 
Atrial fibrillation, n (%) 9 (56.3%) 5 (7.3%) < 0.001 
Heart failure, n (%) 2 (12.5%) 8 11.6%) 0.919 
Peripheral vascular disease, n (%) 
No 
Asymptomatic 
Intermittent claudication 
Amputation  
 
7 (43.8%) 
4 (25%) 
4 (25%) 
1 (6.2%) 
 
26 (37.7%) 
28 (40.6%) 
8 (11.6%) 
7 (10.1%) 
0.420 
Cerebrovascular accident, n (%) 
No 
Stroke 
Other type 
 
14 (87.5%) 
0 (0%) 
2 (12.5%) 
 
62 (89.8%) 
4 (5.8%) 
3 (4.4%) 
0.301 
Vertebral fractures, n (%) 8 (50.0%) 36 (52.2%) 0.875 
Vertebral fractures among men, n (%) 6 (75%) 24 (52.2%) 0.230 
Vertebral fractures among women, n (%) 2 (25%) 12 (52.2%) 0.183 
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Patients 
With DM and 
Warfarin Use 
(n=16, 18.8%) 
Patients 
With DM and No 
Warfarin Use 
 (n=69, 81.2%) p-value 
Routine biochemical profile    
Ca, mg/dl, median 8.94 (8.55, 9.3) 9.04 (8.7, 9.4) 
0.525 
Ca, mg/dl, mean±SD (not normal distributed) 9.02±0.69 9.09±0.57 0.637 
P, mg/dl, mean±SD (not normal distributed) 4.83±0.86 4.58±1.12 0.209 
P, mg/dl, median 4.83 (4.15, 5.60) 4.34 (3.80, 5.2) 0.192 
Alkaline phosphatase, U/L, median 85 (48, 124.5) 87 (65, 110) 0.601 
PTH, pg/ml, median 263 (104.5, 445) 206 (142, 321.3) 0.702 
Albumin, g/dl, median 3.85 (3.3, 4.0) 3.9 (3.5, 4.1) 
0.357 
CRP, mg/L, median 2.5 (0.36, 11.6) 1.90 (0.50, 4.0) 0.725 
KT/V, median 1.21 (1.05, 1.54) 1.26 (1.10, 1.37) 0.951 
Aluminium, mcg/L, median 13 (10, 30) 9 (7, 15) 0.132 
Total cholesterol, mg/dl, median 181.5 (161, 205.5) 173 (150, 193) 0.331 
Triglycerides, mg/dl, median 143.5 (122.5, 214.5) 161 (110, 211) 0.698 
HDL Cholesterol, mg/dl, median 40.5 (32.5, 55.5) 39 (32, 47) 0.396 
LDL Cholesterol, mg/dl, median 105 (76, 118) 94.5 (69, 119) 0.409 
25(OH)D, median 23.9 (16.5, 47.7) 23.2 (16.6, 32.6) 0.589 
BGP total, mcg/L, median 56.2 (37.40, 121.6) 152 (74.8, 230) < 0.001 
ucBGP, mcg/L, median 12.93 (6.1,51.59) 7.94 (2.94, 13.42) 0.064 
23 
 
 
Patients 
With DM and 
Warfarin Use 
(n=16, 18.8%) 
Patients 
With DM and No 
Warfarin Use 
 (n=69, 81.2%) p-value 
MGP total, nmol/L, median 16.72 (11.46, 24.12) 18.42 (12, 34.52) 0.507 
ucMGP, nmol/L, median 336.00 (143, 590) 616 (310.42, 1062) 0.038 
Mg, mg/dL, median (n=26) 2.75 (2.7, 2.8) (n=113) 2.3 (2, 2.6) 0.053 
 331 
 332 
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